A recent study revealed that bevacizumab (Avastin) provides survival benefits in patients with colorectal cancer (CRC) for approximately 2 years after initial administration, aligning with outcomes in ...

The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, but not longer, follow-ups. The benefits of bevacizumab (Avastin) for the ...

aDepartment of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China bDepartment of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China ...